Selenium-containing metallodrug overcomes cervical cancer radioresistance by physical-chemical dual sensitization

Jianrong Cao,Fang Guo,Haiyan Jiang,Chang Liu,Junxian Guo,Fei Cai,Hao Lin,Li Ma,Tianfeng Chen

DOI: https://doi.org/10.1039/d4dt02643h

IF: 4

2024-10-26

Dalton Transactions

Abstract:Radiotherapy is an important treatment for cervical cancer, but the efficacy of radiotherapy is often reduced in clinical practice due to high frequency and high dose radiation leading to radiotherapy resistance. The development of efficient and low-toxicity radiotherapy sensitizers to reduce the radiation dose is one of the effective strategies. Therefore, based on the existing radiotherapy sensitizers responding to radiophysical sensitization radiotherapy, we propose to design radiotherapy sensitizers with enzyme-mimicking properties and dual physical-chemical sensitization radiotherapy. In this work, we constructed Ru-Se complexes with cytochrome P450 enzyme-mimicking properties, and on the one hand, through the complexes to use the high concentration of ROS in the tumor cells to catalyze the oxidation of intracellular active substances, breaking the redox balance of the cells and chemically sensitizing radiotherapy; and on the other hand, through the high atomic number of ruthenium and selenium, responding to the X-ray and physically sensitizing radiotherapy. The experimental results demonstrated that the Ru-Se complexes can efficiently mimic the cytochrome P450 enzyme activity and simultaneously respond to radiation dual sensitization radiotherapy, causing the expression of intracellular DNA damage response proteins, and Inhibition of repair protein expression achieves overcoming radiotherapy resistance. This work provides a new idea for the development of efficient radiation sensitizers in the future.

chemistry, inorganic & nuclear